Welcome to our dedicated page for Cogent Biosciences SEC filings (Ticker: COGT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cogent Biosciences, Inc. (Nasdaq: COGT) SEC filings page on Stock Titan aggregates the company’s official regulatory documents from the U.S. Securities and Exchange Commission. As a biotechnology issuer focused on precision therapies for genetically defined diseases, Cogent uses its filings to disclose material information about clinical progress, financing transactions, and corporate obligations.
Key filings for COGT include current reports on Form 8-K that describe events such as positive top-line results from the SUMMIT, APEX and PEAK trials of bezuclastinib in systemic mastocytosis and gastrointestinal stromal tumors (GIST), Breakthrough Therapy Designation for bezuclastinib in certain NonAdvanced Systemic Mastocytosis populations, and alignment with the U.S. Food and Drug Administration on New Drug Application (NDA) plans. Other 8-Ks detail underwritten public offerings of common stock and 1.625% convertible senior notes due 2031, including the terms of the notes, conversion features, redemption provisions and use of proceeds.
Investors can also review filings that outline lease commitments and headquarters arrangements in Waltham, Massachusetts, as well as periodic financial disclosures furnished via 8-K regarding quarterly results and cash position. Together, these documents provide insight into Cogent’s capital structure, liquidity, and the regulatory and contractual framework supporting its bezuclastinib and broader kinase inhibitor pipeline.
On Stock Titan, Cogent’s SEC filings are updated in near real time as they appear on EDGAR. AI-powered summaries highlight the main points of lengthy documents, helping readers quickly understand complex items such as indentures for convertible notes, underwriting agreements, or detailed clinical data disclosures. Users can easily locate quarterly and annual reports when filed, track material 8-K events, and review information relevant to potential dilution, debt obligations and clinical milestones, all in one organized interface.
Schedule 13G Overview (filed 07/11/2025, event date 07/07/2025)
Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P. and James E. Flynn jointly report beneficial ownership of Cogent Biosciences, Inc. (COGT) common stock.
- Securities class: Common Stock (CUSIP 19240Q201)
- Total shares beneficially owned: 9,053,118
- Percentage of outstanding class: 6.49%
- Voting & dispositive power: All reporting persons share voting and dispositive power over the full 9,053,118 shares; no sole power is reported.
- Reporting persons: Deerfield Mgmt, L.P. (general partner), Deerfield Management Company, L.P. (investment adviser), Deerfield Partners, L.P. (holder of the shares) and James E. Flynn (principal).
- Filing type: Schedule 13G indicates a passive investment intent; the certification expressly states the shares were not acquired to influence control of the issuer.
The filing crosses the 5% ownership threshold, making Deerfield a significant institutional shareholder of Cogent Biosciences. No transactions, purchase prices or changes in ownership levels versus prior periods are disclosed; the document strictly provides current ownership information required under Section 13(d)/(g).